Skip to search formSkip to main contentSkip to account menu

24 HR ropinirole 12 MG Extended Release Oral Tablet [Requip]

Known as: REQUIP XL 12 MG 24HR Extended Release Oral Tablet, Requip XL 12 MG (ropinirole hydrochloride 13.68 MG) 24 HR Extended Release Oral Tablet, ROPINIROLE HYDROCHLORIDE 12 mg ORAL TABLET, FILM COATED, EXTENDED RELEASE [REQUIP XL] 
National Institutes of Health

Related topics

Related topics

19 relations
Carboxymethylcellulose SodiumExtended Release Oral TabletHYDROGENATED CASTOR OILIndigo Carmine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Controlled release behavior and characterization of ropinirole hydrochloride using multi-layer formulation
In this paper, we report cost-effective and simply achievable extended release formulations of ropinirole hydrochloride (RP) by… 
2014
2014
Economic Evaluation of Ropinirole Prolonged Release for Treatment of Parkinson’s Disease in The Netherlands
BackgroundBy using the findings obtained from the PREPARED study, we aimed to estimate the cost effectiveness of ropinirole… 
2013
2013
Практические аспекты применения ропинирола с длительным высвобождением (реквип модутаб) в лечении болезни Паркинсона
Extended-release ropinirole is a new formulation of the well-known nonergolinic D2/D3 dopamine receptor agonist (DRAs), which has… 
2008
2008
Erster oraler, nicht-ergoliner Dopaminagonist in Retardform
Der Wirkstoff Ropinirol als Retardformulierung (ReQuip Modutab®) gilt als neue Behandlungsoption für Parkinson-Patienten, die… 
2004
2004
Management of Parkinson Disease
Parkinson disease is a movement disorder caused by progressive dopaminergic neuron degeneration in the substantia nigra and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)